Celgene Company Profile (NASDAQ:CELG)

Celgene trades on the NASDAQ under the ticker symbol "CELG."

Celgene shares split on the morning of Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly created shares were distributed to shareholders after the market closes on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene stock prior to the split would have 200 shares after the split.

Celgene Co. (NASDAQ:CELG) announced its earnings results on Thursday, April, 27th. The company reported $1.68 EPS for the quarter, beating analysts' consensus estimates of $1.47 by $0.21. The firm had revenue of $2.96 billion for the quarter, compared to analyst estimates of $3.04 billion. Celgene had a return on equity of 77.95% and a net margin of 17.80%. The company's quarterly revenue was up 17.8% compared to the same quarter last year. During the same period last year, the firm posted $1.32 EPS. View Celgene's Earnings History.

Celgene is scheduled to release their next quarterly earnings announcement on Wednesday, July, 26th 2017. View Earnings Estimates for Celgene.

Celgene issued an update on its FY17 earnings guidance on Thursday, April, 27th. The company provided EPS guidance of $7.15-7.30 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.21. The company issued revenue guidance of $13.0-13.4 billion, compared to the consensus revenue estimate of $13.26 billion.

25 brokerages have issued 1 year price targets for Celgene's shares. Their forecasts range from $98.00 to $162.00. On average, they expect Celgene's stock price to reach $139.59 in the next year. View Analyst Ratings for Celgene.

Here are some recent quotes from research analysts about Celgene stock:

• 1. Cann analysts commented, "Celgene unexpectedly reported that Teva submitted an ANDA for Pomalyst, which it intends to defend against. Based on an analysis of Celgene’s patents for Pomalyst, we found that patent lives extend out to 2031. However, Celgene’s documents indicate the date is 2024. We believe this is because Celgene thinks there is an important patent expiring on this date." (4/4/2017)
• 2. According to Zacks Investment Research, "Celgene’s key growth driver, Revlimid, continues to drive revenues at the company. Revlimid continued to outperform on the back of market share gains and increased duration. Other key products – Pomalyst/Imnovid, Abraxane and Otezla – also performed well. Both Otezla and Pomalyst achieved blockbuster status in 2016 recording over $1 billion in sales. Meanwhile, Celgene continues to progress with its label expansion efforts and pipeline development. Label expansion of approved drugs would boost its revenues. Sales of Revlimid are expected to maintain momentum along with Otezla and Pomalyst. Fourth-quarter results were disappointing but the company’s outlook for 2017 was encouraging. Shares of Celgene have outperformed the industry in the past one year. However, Celgene is highly dependent on Revlimid for growth. Stiff competition in target markets is another concern." (3/9/2017)
• 3. Robert W. Baird analysts commented, "Celgene reported positive top-line data from the SUNBEAM trial of ozanimod in multiple sclerosis. Though no numbers were provided, it looks like the primary and key secondary endpoints were met, with a similar safety profile versus the Phase 2 studies. Though we find the lack of additional safety issues encouraging, success also depends on ability to compete with Gilenya, Tecfidera, and Roche's Ocrevus on efficacy. More complete data won't be available until later this half." (2/17/2017)
• 4. Jefferies Group LLC analysts commented, "Though updates were mostly incremental given recent pre-reporting, the review of sales dynamics, 2017 guidance, and pipeline progress reaffirms our expectation for best-in-class medium-term growth from healthy core franchises. We expect continued strong execution throughout the year and lower-risk catalysts to drive appreciation towards levels reflecting underappreciated prospects of their products and portfolio." (1/27/2017)

Some companies that are related to Celgene include Amgen (AMGN), Gilead Sciences (GILD), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Grifols SA, Barcelona (GRFS), Incyte (INCY), Illumina (ILMN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Seattle Genetics (SGEN), Jazz Pharmaceuticals plc - (JAZZ), TESARO (TSRO), Alnylam Pharmaceuticals (ALNY), Exelixis (EXEL), BIO-TECHNE Corp (TECH), Kite Pharma (KITE) and Galapagos NV (GLPG).

Celgene's management team includes the folowing people:

• Robert J. Hugin, Executive Chairman of the Board
• Scott A. Smith, President, Chief Operating Officer
• Mark J. Alles, Chief Executive Officer, Director
• Peter N. Kellogg, Chief Financial Officer, Executive Vice President
• Terrie Curran, President, Global Inflammation & Immunology Franchise
• Michael F. Pehl, President, Hematology & Oncology
• Rupert J. Vessey, President - Research and Early Development
• Gerald F. Masoudi, Executive Vice President, General Counsel and Corporate Secretary
• Michael D. Casey, Lead Independent Director
• Michael W. Bonney, Director

Celgene's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.87%), Vanguard Group Inc. (6.65%), State Street Corp (4.16%), Jennison Associates LLC (1.70%), FMR LLC (1.52%) and Bank of New York Mellon Corp (1.30%). Company insiders that own Celgene stock include Corp /De/ Celgene, Ernest Mario, Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Michael W Bonney, Richard W Barker, Robert J Hugin, Rupert Vessey and Thomas O Daniel. View Institutional Ownership Trends for Celgene.

Celgene's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Jennison Associates LLC, Winslow Capital Management LLC, Parametric Portfolio Associates LLC, Renaissance Technologies LLC, Janus Capital Management LLC, Marshall Wace LLP and TCW Group Inc.. Company insiders that have sold Celgene stock in the last year include Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Richard W Barker, Robert J Hugin and Rupert Vessey. View Insider Buying and Selling for Celgene.

Celgene's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Bank of Montreal Can, Investec Asset Management LTD, OppenheimerFunds Inc., Wellington Management Group LLP, State Street Corp and Pioneer Investment Management Inc.. Company insiders that have bought Celgene stock in the last two years include Corp /De/ Celgene and Michael W Bonney. View Insider Buying and Selling for Celgene.

Shares of Celgene can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Celgene stock can currently be purchased for approximately $116.78.